Eli Lilly has become the first healthcare company to reach a $1 trillion market valuation, fueled by strong sales of its weight loss drugs like Mounjaro and Zepbound. The company reported a 55.5% revenue increase year-over-year to $19.8 billion in the latest quarter and raised its full-year revenue forecast to $82-$85 billion. Despite this growth, pricing pressures and lower international margins, especially in China, pose challenges. Competitors like Pfizer and Novo Nordisk are aggressively investing to capture market share in the expanding obesity treatment market projected to reach $120 billion by 2035.
BioArctic has entered a research collaboration with Eli Lilly to develop a new neurodegenerative disease treatment using BioArctic's BrainTransporter technology combined with a Lilly drug candidate. BioArctic will receive $30 million upfront and coul...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
Eli Lilly reported a 55.5% revenue increase in Q1 to $19.8 billion, led by $8.66 billion from Mounjaro, and raised its full-year revenue guidance to $82-$85 billion. Despite strong fundamentals, the stock has been stuck near $1,100 due to concerns ov...
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
